Salarius Announces Issuance of New Patent for Seclidemstat by European Patent Office

New Patent Protects Composition of Matter and Methods of Use Through At Least August 2032

HOUSTON, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced the continued enhancement of the intellectual property (IP) portfolio governing its lead investigational drug candidate, seclidemstat. The European Patent Office (EPO) recently announced that the European Patent EP2744330, exclusively licensed to Salarius from the University of Utah Research Foundation, was issued on July 15, 2020. 

The European patent covers composition of matter and methods of use for seclidemstat, a potent reversible inhibitor of the LSD1 enzyme which is currently the subject of a Phase 1/2 clinical trial for Ewing sarcoma, a rare pediatric bone cancer, and a Phase 1/2 trial in advanced solid tumors (AST). Salarius intends to validate this European patent in several important EU countries, ensuring protection of seclidemstat and other compounds in Europe through at least August 2032.

“This is an important advancement in our efforts to broaden our global patent estate for seclidemstat,” said David Arthur, President and Chief Executive Officer of Salarius. “To date, our intellectual property portfolio spans multiple patents and patent applications in the U.S., EU, and numerous additional countries.”

In all, Salarius holds 24 issued patents in the U.S. and abroad. The company’s current IP estate includes five patents issued in the U.S. and another 19 patents issued in Europe, Australia, Brazil, China, Eurasia, Israel, India, Japan, Korea, Mexico, New Zealand, Singapore and South Africa. Salarius also has nine patent applications pending approval in Brazil, Canada, Israel, India, Korea, Singapore and China. All 24 issued patents and the nine pending applications are directed to seclidemstat or structurally similar compounds.

About Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, or epigenetic causes of cancers, and is developing treatments for patients that need them the most. Epigenetics refers to the regulatory system that affects gene expression. Salarius’ lead candidate, seclidemstat, is currently in clinical development for treating Ewing sarcoma, for which it has Fast Track Designation, Orphan Drug Designation and Rare Pediatric Disease Designation by the U.S. Food and Drug Administration. Salarius is also developing seclidemstat for a number of cancers, with a second Phase 1/2 clinical study in advanced solid tumors, including prostate, breast and ovarian cancers.